Skip to main content
Caplight Logo









Maculaser

Maculaser

Private
EspooHealthcare & Life Scienceshttps://maculaser.com/

Last Round

VC Round

Aug 11, 2026

Total Funding Raised

$1.44M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Maculaser is a medical technology company that develops patented, temperature-controlled retinal laser therapy designed to treat retinal diseases such as age-related macular degeneration, diabetic macular edema, and central serous chorioretinopathy.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Biotechnology

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Application

Keywords

retinal laser therapyophthalmology devicemedtechage-related macular degenerationAMDdiabetic macular edemaDMEcentral serous chorioretinopathyCSCmedical hardwareeye care technologyretinal disease treatmentlaser eye surgerynon-invasive eye treatmentusage-based billing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Maculaser Comparables

Compare Maculaser with similar companies based on industry and business-model similarity.

Maculaser comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OD-OS GmbH
82%
Norlase
79%
Nova Eye Medical Ltd
76%

Maculaser Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 11, 2026
SeedFeb 10, 2021

Key People

Founding team and executive leadership

Jani Tirronen

CEO & Co-Founder

Founding Team

Jaakko Nieminen

Chief Technology Officer

Executive Team

Maculaser Investors

Notable investors and investment history

Maculaser investors
InvestorRounds
InnovestorVC Round, Seed
M2careVC Round
ZEISS VenturesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 11, 2026

    $5.08M round led by ZEISS Ventures and M2care

  • Jun 18, 2026

    Monthly visitors grew 216% MoM, from 116 to 366.

Maculaser Filings

Explore SEC and related filing metadata, where available.

Maculaser filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Maculaser's valuation, stock price, and market status.

Is Maculaser a public or private company?

Maculaser is a private company.

What is the current stock price of Maculaser?

Maculaser is a private company, so its shares have no public market price. Caplight tracks Maculaser's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Maculaser worth (valuation)?

Valuation information for Maculaser is not publicly available.

Can I buy Maculaser stock?

Maculaser shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Maculaser's last funding round?

Maculaser's most recent funding round was VC Round on August 11, 2026.

Who are the main investors in Maculaser?

Key investors in Maculaser include Innovestor, M2care, ZEISS Ventures.

Will Maculaser IPO soon?

No public IPO plans have been announced for Maculaser.

How can I track Maculaser secondary market activity?

Caplight tracks bids, offers, and trades in Maculaser's shares on secondary markets.

Firmographic Details

HeadquartersEspoo
Employee Range6
Year Founded2020
Last FundingAug 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?